{"id":"8042a378-3677-509e-95a3-aa13210cc4d8","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:b3-cons-nicotinamide-sarm-inhibition","predicate":"inhibits","statement":"Nicotinamide inhibited purified human SARM1 TIR NADase activity, with an assay IC50 of 43.8 micromolar.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"99aae55c-4cfb-5dfd-bd8b-5000c186e333","mechanism_event_label":"A product of NAD cleavage fed back to inhibit the isolated SARM1 domain.","subject":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"object":{"id":"34873c2d-4607-5dc7-8cd5-d443adb3365d","slug":"sarm1-tir-domain","display_name":"Human SARM1 TIR-domain construct","entity_type_key":"protein_state"},"evidence_count":1,"mechanism_event":{"id":"99aae55c-4cfb-5dfd-bd8b-5000c186e333","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:b3-cons-nicotinamide-sarm-inhibition-event","event_type":"biochemical_relationship","label":"A product of NAD cleavage fed back to inhibit the isolated SARM1 domain.","description":"Nicotinamide inhibited purified human SARM1 TIR NADase activity, with an assay IC50 of 43.8 micromolar.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"role":"inhibitor","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"34873c2d-4607-5dc7-8cd5-d443adb3365d","slug":"sarm1-tir-domain","display_name":"Human SARM1 TIR-domain construct","entity_type_key":"protein_state"},"role":"enzyme","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"substrate","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"false","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-consumption-sources/sarm2017.txt\", \"locator\": \"Full text, normalized paragraph 25\", \"start_char\": 16947, \"end_char\": 18260, \"file_sha256\": \"fc30de231911f5c30425173d684495e62c725ba27c78d44592e6bc68433ef545\", \"text_sha256\": \"bf110010a793c4d1d3c263db9f213aa5d539bcf1501265fe30fb1ab9ed4028fa\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Purified domain dose-response assay","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nicotinamide titration; starting NAD+ about 5 micromolar","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Purified engineered TIR fragment rather than basal activity of intact full-length SARM1; no dietary dose inference. IC50 depends on assay conditions and is not a therapeutic plasma target.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A product of NAD cleavage fed back to inhibit the isolated SARM1 domain.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b3-cons-sarm2017] The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. (2017). https://pubmed.ncbi.nlm.nih.gov/28334607/ DOI: 10.1016/j.neuron.2017.02.022","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Cell-free preparation","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4db6487b-b69e-5f89-8a78-3db7a6509224","evidence_kind":"source_excerpt","locator":"Lines 705-717","start_line":705,"end_line":717,"excerpt":"### b3-cons-nicotinamide-sarm-inhibition\nNicotinamide inhibited purified human SARM1 TIR NADase activity, with an assay IC50 of 43.8 micromolar.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A product of NAD cleavage fed back to inhibit the isolated SARM1 domain.\norganism: Human\ntissue_or_cell_type: Cell-free preparation\nexperimental_model: Purified domain dose-response assay\nlimitations: Purified engineered TIR fragment rather than basal activity of intact full-length SARM1; no dietary dose inference. IC50 depends on assay conditions and is not a therapeutic plasma target.\nexposure: Nicotinamide titration; starting NAD+ about 5 micromolar\ncross_nutrient: false\nevidence_span: {\"source_cache\": \"artifacts/niacin-consumption-sources/sarm2017.txt\", \"locator\": \"Full text, normalized paragraph 25\", \"start_char\": 16947, \"end_char\": 18260, \"file_sha256\": \"fc30de231911f5c30425173d684495e62c725ba27c78d44592e6bc68433ef545\", \"text_sha256\": \"bf110010a793c4d1d3c263db9f213aa5d539bcf1501265fe30fb1ab9ed4028fa\"}\n[b3-cons-sarm2017] The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. (2017). https://pubmed.ncbi.nlm.nih.gov/28334607/ DOI: 10.1016/j.neuron.2017.02.022","model_system":"Purified domain dose-response assay","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b3-cons-sarm2017] The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. (2017). https://pubmed.ncbi.nlm.nih.gov/28334607/ DOI: 10.1016/j.neuron.2017.02.022","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}